Treatment with combined dabrafenib and trametinib in BRAFV600E-mutated metastatic malignant melanoma: a case of long-term complete response after treatment cessation

Sonia Brugnara; Mariacristina Sicher; Elena Maria Bonandini; Davide Donner; Franca Chierichetti; Mattia Barbareschi; Carlo Renè Girardelli; Orazio Caffo

doi:10.7573/dic.212515

Treatment with combined dabrafenib and trametinib in BRAF^V600E-mutated metastatic malignant melanoma: a case of long-term complete response after treatment cessation

Drugs Context. 2018 Feb 15:7:212515. doi: 10.7573/dic.212515. eCollection 2018.

Authors

Sonia Brugnara¹, Mariacristina Sicher², Elena Maria Bonandini³, Davide Donner⁴, Franca Chierichetti⁴, Mattia Barbareschi³, Carlo Renè Girardelli², Orazio Caffo¹

Affiliations

¹ Oncology Unit, S. Chiara Hospital, Trento, Italy.
² Dermatology Unit, S. Chiara Hospital, Trento, Italy.
³ Pathology Unit, S. Chiara Hospital, Trento, Italy.
⁴ Nuclear Medicine, S. Chiara Hospital, Trento, Italy.

Abstract

Here, we report the case of a patient, diagnosed with BRAF^V600E-mutated metastatic malignant melanoma M1a, who achieved a complete metabolic response after 7 months of treatment with the combination of dabrafenib and trametinib. After 31 months, the treatment was interrupted for patient's decision. To date October 2017, 18 months after the interruption of the treatment with the combination of dabrafenib and trametinib, follow-up Positron Emission Tomography (PET) scans are still documenting complete metabolic response.

Keywords: case report; complete remission; dabrafenib; drug combination; melanoma; neoplasm metastasis; vemurafenib.

Publication types

Case Reports